Human interleukin-2

Generic Name
Human interleukin-2
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
FNO32LO217
Background

Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).

Associated Conditions
-
Associated Therapies
-
nature.com
·

Safety and efficacy assessment of fecal microbiota transplantation as an adjunctive

15 participants (5 females, 10 males) showed varying degrees of urinary protein reduction post-treatment; 6 with >50% decrease, 9 with <50%. Mean 24-h urinary protein quantification pre-enrollment was 1.15 ± 0.94 g/day. Gastrointestinal symptoms improved in all post-treatment. 24-h urinary protein quantification decreased significantly at 1 and 3 months post-FMT, excluding 2 with acute infections. Specific urinary proteins and most immune cells/cytokines showed no significant changes. B cell counts decreased significantly post-FMT. Safety indicators showed no significant changes except for serum sodium and calcium. No severe adverse events reported. Gut microbiota composition changed post-FMT, with correlations noted between specific bacteria and B cell changes. Intestinal metabolite composition also changed, with correlations found between specific metabolites and B cells, serum calcium, and sodium.
forbes.com
·

Mural Oncology Highlights Clinical Trials During Its Maiden Investor Day

Mural Oncology's virtual Investor Day highlighted progress in its lead candidate, Nemvaleukin, an engineered IL-2 cytokine showing promising efficacy in combination with pembrolizumab. The phase 3 ARTISTRY-7 trial for platinum-resistant ovarian cancer and phase 2 ARTISTRY-6 trial for mucosal melanoma are fully enrolled, with key data expected in early to mid-2025. The company also discussed its IL-18 program, with an IND submission planned for Q4 2025. Mural's fair value estimate is $12.00 per share, with a 'Long-Term Buy' rating and an implied upside of 293.4%.
biospace.com
·

Mural Oncology's First Virtual Investor Day to Highlight Late-Stage Clinical Progress

Mural Oncology to host virtual Investor Day, sharing insights on nemvaleukin trial design, statistical assumptions, and progress. Key data readouts for nemvaleukin in platinum-resistant ovarian cancer and mucosal melanoma expected in late Q1/early Q2 2025. IND submission for Mural’s IL-18 program planned for Q4 2025.
marketscreener.com
·

Medicenna Announces Results of Annual Meeting of Shareholders

Medicenna Therapeutics Corp. announced the results of its annual shareholder meeting on September 26, 2024, where all nominees were elected as directors. Shareholders also voted for MNP LLP as the auditor. 45.89% of common shares were represented at the meeting.
themedicinemaker.com
·

Biopharmaceuticals: Simplifying Complexity With mRNA

mRNA-based protein therapeutics overcome traditional recombinant protein development challenges, offering faster development, improved specificity, and broader therapeutic applicability.

Award-winning German-Cuban cooperation in cancer therapy

Dr. Gertrudis Rojas Dorantes of the Cuban Centro de Inmunología Molecular visits TU Braunschweig for the sixth time, collaborating with Dr. Maren Schubert to improve cancer treatment using advanced biotechnological methods. Their work has led to five publications and a Research Prize from the Cuban Academy of Sciences, with potential for better cancer therapies within the next decade.
prnewswire.com
·

Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology

The 2024 ESMO Annual Congress in Barcelona showcased Biosyngen's gene-modified TILs from liver cancer biopsies, with BRG01 in Phase II trials for solid tumors. Biosyngen's TIL platform includes efficient TIL manufacturing, stable gene modification, enhanced TIL persistence, and strong antitumor efficacy without IL-2.
nature.com
·

Phase I study of safety and efficacy of allogeneic natural killer cell therapy in relapsed

Article references on neuroblastoma treatments, including advances in therapy, risk classification, and immunotherapy, with focus on NK cell-based strategies and clinical trials.
© Copyright 2024. All Rights Reserved by MedPath